These innovative compounds represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://nanaawkm694981.blogprodesign.com/60335005/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide